Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice

---
identifier: "/us/fr/2017-04529"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice"
title_number: 0
title_name: "Federal Register"
section_number: "2017-04529"
section_name: "Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice"
positive_law: false
currency: "2017-03-08"
last_updated: "2017-03-08"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2017-04529"
document_type: "notice"
publication_date: "2017-03-08"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "82 FR 12968"
fr_volume: 82
docket_ids:
  - "Docket No. FDA-2017-N-0067"
fr_action: "Notice."
---


#  Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The Food and Drug Administration (FDA) is announcing an amendment to the notice of the joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. This meeting was announced in the *Federal Register* of January 11, 2017. The amendment is being made to reflect a change in the *ADDRESSES* portion of the document. There are no other changes.

**FOR FURTHER INFORMATION CONTACT:**

Stephanie L. Begansky, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, email: *[email protected],* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of January 11, 2017 (82 FR 3333), FDA announced that the joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee would be held on March 13-14, 2017. On page 3334, in the first column, under the *ADDRESSES* caption, the address of the meeting and the phone number in the first six lines is changed to read as follows:

**ADDRESSES:**

The meeting will be held at the Tommy Douglas Conference Center, 10000 New Hampshire Ave., Silver Spring, MD 20903. The conference center's telephone number is 240-645-4000.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: March 3, 2017.

Janice M. Soreth,

Associate Commissioner for Special Medical Programs.